Back

Impact of sodium-glucose cotransporter-2 inhibitors on survival in patients with cancer therapy-related cardiac dysfunction

20 June 2025 (00:00 - 00:00)
Organised by: Logo
Congress Presentation Part of: Novel strategies for prevention in cardio-oncology Diagnosis and Management of Cardiovascular Disease in Patients with Cancer CCO Premium Access ESC Cardio-Oncology 2025 Council of Cardio-Oncology

About the speaker

Photo
Associate Professor Reza Arsanjani

Mayo Clinic, Scottsdale (United States of America)

5 More presentations in this session

Presentation thumbnail
Effect of statin on right ventricle function in breast cancer patients treated with anthracycline
Associate Professor K. Mindadze (Tbilisi, GE)
Abstract Slides
Presentation thumbnail
Gliflozines in active cancer patients with heart failure: final results on safety and effectiveness in the observational TOSCA trial
Doctor I. Fabiani (Pisa, IT)
Abstract Slides
Presentation thumbnail
Revisiting the role of angiotensin-converting enzyme inhibitors in preventing chemotherapy cancer related cardiac disease in paediatric malignant bone tumours patients
Professor Z. Seliem (Cairo, EG)
Abstract Slides
Presentation thumbnail
Sacubitril/Valsartan and cardiovascular outcomes in cancer patients on anthracycline therapy: a global health research network retrospective analysis
Doctor L. Gioli-Pereira (Sao Paulo, BR)
Abstract Slides
Presentation thumbnail
Prevention of radiation induced cardiotoxicity in patients with left sided breast cancer: results from a phase 2 clinical trial
Doctor I. Paterson (Ottawa, CA)
Abstract Slides

Access the full session

Session thumbnail
Novel strategies for prevention in cardio-oncology

The Event

Event poster

ESC Cardio-Oncology 2025

20 June - 21 June 2025

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources